Imlygic

Asia

Japan's Oncolys plans to test Imlygic rival in melanoma

Japan's Oncolys BioPharma wants to muscle in on Amgen's cancer-killing virus for melanoma. The biotech has filed to start trials of its version in U.S. melanoma patients, just a few months after the Amgen product was cleared by the FDA.

Phil Taylor Sep 5, 2016 12:13pm

NICE watchdogs decide to back Amgen's Imlygic after all

Aug 9, 2016 9:52am